In a B16 melanoma model expressing HER2, treatment with a CD1d-antibody fusion protein targeting HER2 increased iNKT cell inflammatory cytokine production and targeted lysis of tumor cells, decreasing metastasis formation [114]. Here, ERBB2 is linked to melanoma.